Key takeaway: During the Q1 FY27 earnings conference call, management reported a challenging operating environment due to the ongoing West Asia conflict, which affected raw material costs and logistics. Despite these challenges, Epigral Limited achieved a 15% revenue growth, reaching INR 709 crores, and maintained an EBITDA margin of 25%. Management highlighted the resilience of their diversified product portfolio, which helped offset difficulties in certain segments. They announced ongoing capacity expansions for Epichlorohydrin and CPVC Resin, along with a strategic capex plan for two new projects in Epoxy Resin & Formulations and a multipurpose plant. The CFO provided financial details, noting a 25% increase in PAT to INR 99 crores. Management expressed confidence in the long-term growth potential of their products and the Indian market, while also addressing questions regarding capacity utilization and market dynamics.

Key takeaway: Epigral Limited reported its Q1 FY27 financial results, highlighting a 15% year-over-year revenue growth to ₹709 Crore, driven by a 5% increase in sales volume and improved realization. The company's EBITDA rose by 10% to ₹179 Crore, with an EBITDA margin of 25%. Profit After Tax (PAT) increased by 25% to ₹99 Crore, resulting in a PAT margin of 14%. The company noted a Return on Capital Employed (ROCE) of 16%, down from 24% in Q1 FY26, attributed to lower EBIT and significant capital work in progress. Management announced the approval of capital expenditures for an Epoxy Resin & Formulations plant and a Multi-Purpose Plant, both set to enhance operational efficiency and cater to growing domestic demand across various sectors. The presentation emphasized the company's commitment to diversifying its portfolio and building an integrated manufacturing platform.

Key takeaway: During the Q4 FY26 conference call, management reported that Epigral Limited achieved its highest-ever revenue of INR 736 crores, reflecting a 15% quarter-on-quarter and 14% year-on-year volume growth. The company noted that the chemical industry faced volatility due to geopolitical tensions, which disrupted global supply chains and affected raw material availability. Despite these challenges, management highlighted a normalized EBITDA margin of 23% due to improved plant utilization and stable raw material prices. For the full fiscal year, revenue decreased slightly by 1% to INR 2,542 crores, attributed to a 4% drop in volume. Management set a goal of 10% to 12% volume growth for FY27, supported by ongoing capacity expansion projects. The call concluded with management emphasizing their commitment to consistent growth and diversification across multiple product lines.

Key takeaway: Epigral Limited's investor presentation on audited financial results for Q4 and FY2026 reported a record revenue of ₹736 Crore, reflecting a 22% growth driven by a 15% increase in sales volume. The presentation highlighted that EBITDA rose by 64% to ₹169 Crore, with an EBITDA margin of 23%. However, Q4 revenue decreased by 1% to ₹2,542 Crore due to a 4% drop in sales volume. The company reported a PAT of ₹333 Crore, with a PAT margin of 11%. For FY2026, the board proposed a final dividend of ₹5 per share and noted a capital expenditure of ₹394 Crore. Management indicated that ongoing capex projects for CPVC and Epichlorohydrin are progressing as planned. The company received the EcoVadis Silver Medal and renewed its Responsible Care certification for three years.

Key takeaway: During the earnings call for Q3 FY26, management reported a mixed performance in the chemical market, with some segments showing robust growth while others faced challenges due to a prolonged monsoon and geopolitical uncertainties. Revenues grew marginally by 2% sequentially, with the derivatives and specialty business contributing 52% of total revenue. EBITDA margins contracted to 17% due to lower realizations and rising raw material costs. Management noted a recovery in demand since mid-November and expressed optimism about sustained growth in future quarters. The capex projects to double capacity at key plants are on schedule, with plans to enhance the integrated complex and extend the value chain. Management emphasized a focus on scalable, profitable growth and disciplined execution to deliver sustainable results. The call concluded with management reiterating their commitment to consistent growth and diversification across multiple products.